ADX10059 in anxiety
Addex tested ADX10059 in anxiety because clinical and preclinical research has shown that mGluR5 blockers are effective anxiolytic (anti-anxiety) agents. In a small Phase IIa proof of concept trial in patients with acute anticipatory dental anxiety, ADX10059 did not demonstrate a statistically significant effect. Nevertheless, because of the wealth of clinical and preclinical data supporting mGluR5 inhibition as an effective anxiolytic strategy, Addex believes that ADX10059 still has potential in chronic forms of anxiety.
Addex has decided it will not pursue further clinical development of ADX10059 for anxiety because of the necessary size, cost and complexity of the chronic anxiety trials. This decision was facilitated by the fact that Addex expects that potential partners interested in ADX10059 will want to negotiate rights to study it in anxiety, in addition to GERD and migraine.